You just read:

T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer's Disease.

News provided by

T3D Therapeutics, Inc.

Nov 04, 2019, 07:30 ET